- A step towards the ambition of precision oncology in recurrent ovarian cancer
-
Wijaya ST, Tan DSP
- KMID: 2537901
- J Gynecol Oncol.
- 2022 Jul;33(4):e64.
- doi: 10.3802/jgo.2022.33.e64
-
- CITED
-
- Close
- SHARE
-
- Close
- Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
-
Shi T, Xiang L, Zhu J, Liu J, Zhang P, Wang H, Feng Y, Zhu T, Zhang Y, Yu A, Jiang W, Wang X, Zhu Y, Wu S, Teng Y, Zhang J, Jiang R, Zhang W, Jia H, Zang R
- KMID: 2537900
- J Gynecol Oncol.
- 2022 Jul;33(4):e63.
- doi: 10.3802/jgo.2022.33.e63
-
- CITED
-
- Close
- SHARE
-
- Close
- Turning up the heat does not affect quality of life
-
van Driel WJ, Aronson SL, van Stein RM, Sonke GS
- KMID: 2537902
- J Gynecol Oncol.
- 2022 Jul;33(4):e68.
- doi: 10.3802/jgo.2022.33.e68
-
- CITED
-
- Close
- SHARE
-
- Close
- Book Review: IARC handbooks of cancer prevention, volume 18: Cervical cancer screening
-
Kim SI, Kim JW
- KMID: 2537903
- J Gynecol Oncol.
- 2022 Jul;33(4):e65.
- doi: 10.3802/jgo.2022.33.e65
-
- CITED
-
- Close
- SHARE
-
- Close
- Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)
-
Asano H, Oda K, Yoshihara K, Ito YM, Matsumura N, Shimada M, Watari H, Enomoto T
- KMID: 2537899
- J Gynecol Oncol.
- 2022 Jul;33(4):e55.
- doi: 10.3802/jgo.2022.33.e55
Background Poly (adenosine diphosphate)-ribose polymerase (PARP) inhibitors for tumors with homologous recombination deficiency (HRD), including pathogenic mutations in BRCA1/2, have been developed. Genomic analysis revealed that about 20% of uterine leiomyosarcoma... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis
-
Kengsakul M, Nieuwenhuyzen-de Boer GM, Udomkarnjananun S, Kerr SJ, Niehot CD, Beekhuizen HJv
- KMID: 2537896
- J Gynecol Oncol.
- 2022 Jul;33(4):e53.
- doi: 10.3802/jgo.2022.33.e53
Objective Advances in ovarian cancer cytoreductive surgery have enabled more extensive procedures to achieve maximal cytoreduction but with a consequent increase in postoperative morbidity and mortality. The aim of this study... -
- CITED
-
- Close
- SHARE
-
- Close
- Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)
-
Kim JH, Lee De, Lee Y, Ha HI, Chang YJ, Chang SJ, Park SY, Lim MC
- KMID: 2537897
- J Gynecol Oncol.
- 2022 Jul;33(4):e54.
- doi: 10.3802/jgo.2022.33.e54
Objective To investigate the health-related quality of life (HRQOL) related to hyperthermic intraperitoneal chemotherapy (HIPEC) following primary or interval cytoreductive surgery for primary ovarian cancer. Methods Between 2010 and 2016, a total of... -
- CITED
-
- Close
- SHARE
-
- Close
- Bone health after RRBSO among BRCA1/2 mutation carriers: a population-based study
-
Valle HAd, Kaur P, Kwon JS, Cheifetz R, Dawson L, Hanley GE
- KMID: 2537898
- J Gynecol Oncol.
- 2022 Jul;33(4):e51.
- doi: 10.3802/jgo.2022.33.e51
Objective Examine the risks of fractures and osteoporosis after risk-reducing bilateral salpingo-oophorectomy (RRBSO) among women with BRCA1/2 mutations. Methods In this retrospective population-based study in British Columbia, Canada, between 1996 to 2017, we... -
- CITED
-
- Close
- SHARE
-
- Close
- TP53 variants in p53 signatures and the clonality of STICs in RRSO samples
-
Akahane T, Masuda K, Hirasawa A, Kobayashi Y, Ueki A, Kawaida M, Misu K, Nakamura K, Nagai S, Chiyoda T, Yamagami W, Hayashi S, Kataoka F, Banno K, Sugano K, Okita H, Kosaki K, Nishihara H, Aoki D
- KMID: 2537895
- J Gynecol Oncol.
- 2022 Jul;33(4):e50.
- doi: 10.3802/jgo.2022.33.e50
Objective Precursor lesions may be identified in fallopian tube tissue after risk-reducing salpingo-oophorectomy (RRSO) in patients with pathogenic variants of BRCA1/2. Serous tubal intraepithelial carcinoma (STIC) is considered a precursor of... -
- CITED
-
- Close
- SHARE
-
- Close
- Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy
-
Sekine M, Enomoto T, Arai M, Den H, Nomura H, Ikeuchi T, Nakamura S, the Registration Committee of the Japanese Organization of Hereditary Breast and Ovarian Cancer
- KMID: 2537893
- J Gynecol Oncol.
- 2022 Jul;33(4):e46.
- doi: 10.3802/jgo.2022.33.e46
Objective BRCA1 and BRCA2 mutation carriers are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) by age 40 and 45, respectively. However, the carriers have a different way of thinking about their life... -
- CITED
-
- Close
- SHARE
-
- Close
- Associations between obesity, metabolic syndrome, and endometrial cancer risk in East Asian women
-
Park B
- KMID: 2537889
- J Gynecol Oncol.
- 2022 Jul;33(4):e35.
- doi: 10.3802/jgo.2022.33.e35
Objective This study investigated the associations between obesity, metabolic syndrome (MetS), the combination of these two components as a metabolic obesity phenotype, and endometrial cancer risk in East Asian women. Methods A total... -
- CITED
-
- Close
- SHARE
-
- Close
- Diagnostic performance of microRNA-34a, let-7f and microRNA-31 in epithelial ovarian cancer prediction
-
Kumar V, Gupta S, Varma K, Chaurasia A, Sachan M
- KMID: 2537894
- J Gynecol Oncol.
- 2022 Jul;33(4):e49.
- doi: 10.3802/jgo.2022.33.e49
Objective To correlate the genome-wide methylation signature of microRNA genes with dysregulated expression of selected candidate microRNA in tissue and serum samples of epithelial ovarian cancer (EOC) and control using quantitative... -
- CITED
-
- Close
- SHARE
-
- Close
- Trends in cervical cancer screening rates among Korean women: results of the Korean National Cancer Screening Survey, 2005–2020
-
Shin HY, Lee YY, Song SY, Park B, Suh M, Choi KS, Jun JK
- KMID: 2537890
- J Gynecol Oncol.
- 2022 Jul;33(4):e39.
- doi: 10.3802/jgo.2022.33.e39
Objective This study aimed to analyze the trends in cervical cancer screening rates, including organized and opportunistic cancer screening rates, with the Papanicolaou test among Korean women. Methods Data were collected from a... -
- CITED
-
- Close
- SHARE
-
- Close
- Survival benefits of retroperitoneal lymphadenectomy for optimally-resected advanced ovarian high-grade serous carcinoma: a multi-institutional retrospective study
-
Ikeda Y, Yoshihara M, Tamauchi S, Yokoi A, Yoshikawa N, Kajiyama H
- KMID: 2537891
- J Gynecol Oncol.
- 2022 Jul;33(4):e40.
- doi: 10.3802/jgo.2022.33.e40
Objective The survival benefits of retroperitoneal lymphadenectomy (RLNA) for epithelial ovarian cancer (EOC) remain controversial because clinical behaviors differ among subtypes. The purpose of the present study was to clarify whether... -
- CITED
-
- Close
- SHARE
-
- Close
- Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial
-
Lee JY, Kim BG, Kim JW, Lee JB, Park E, Joung JG, Kim S, Choi CH, Kim HS, on behalf of Korean Gynecologic Oncology Group (KGOG) investigators
- KMID: 2537892
- J Gynecol Oncol.
- 2022 Jul;33(4):e45.
- doi: 10.3802/jgo.2022.33.e45
Objective Management of heavily pre-treated platinum-resistant ovarian cancer remains a therapeutic challenge. Outcomes are poor with non-platinum, single-agent chemotherapy (CT); however, molecularly targeted anticancer therapies provide new options. Methods This open-label, investigator-initiated, phase... -
- CITED
-
- Close
- SHARE
-
- Close
